|
|
Prepublished online as a Blood First Edition Paper on December 12, 2002; DOI 10.1182/blood-2002-05-1589.

Submitted June 5, 2002
Accepted November 23, 2002
AML1/MTG8 Oncogene Suppression by Small Interfering RNAs Supports Myeloid Differentiation of t(8;21)-positive Leukemic Cells
Olaf Heidenreich*, Juergen Krauter, Heidemarie Riehle, Philipp Hadwiger, Matthias John, Gerhard Heil, Hans-Peter Vornlocher, and Alfred Nordheim
Molecular Biology, University of Tuebingen, Tuebingen, Germany
Hematology and Oncology, Medical School Hannover, Hannover, Germany
Ribopharma AG, Kulmbach, Germany
* Corresponding author; email: olaf.heidenreich{at}uni-tuebingen.de.
The translocation t(8;21) yields the leukemic fusion gene AML1/MTG8 and is associated with 10-15% of all de novo cases of acute myeloid leukemia. We demonstrate the efficient and specific suppression of AML1/MTG8 by small interfering RNAs (siRNAs) in the human leukemic cell lines Kasumi-1 and SKNO-1. siRNAs targeted against the fusion site of the AML1/MTG8 mRNA reduce the levels of AML1/MTG8 without affecting the amount of wildtype AML1. These data argue against a transitive RNA interference mechanism potentially induced by siRNAs in such leukemic cells. Depletion of AML1/MTG8 correlates with an increased susceptibility of both Kasumi-1 and SKNO-1 cells to TGF 1/vitamin D3-induced differentiation, leading to increased expression of CD11b, M-CSF receptor and C/EBP . Moreover, siRNA-mediated AML1/MTG8 suppression results in changes in cell shape, and, in combination with TGF 1/vitamin D3, severely reduces clonogenicity of Kasumi-1 cells. These results suggest an important role for AML1/MTG8 in preventing differentiation, thereby propagating leukemic blast cells. Therefore, siRNAs are promising tools for a functional analysis of AML1/MTG8, and may be used in a molecularly defined therapeutic approach for t(8;21)-positive leukemia.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Osman, V. Gobert, F. Ponthan, O. Heidenreich, M. Haenlin, and L. Waltzer
A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO
PNAS,
July 21, 2009;
106(29):
12043 - 12048.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Corsello, G. Roti, K. N. Ross, K. T. Chow, I. Galinsky, D. J. DeAngelo, R. M. Stone, A. L. Kung, T. R. Golub, and K. Stegmaier
Identification of AML1-ETO modulators by chemical genomics
Blood,
June 11, 2009;
113(24):
6193 - 6205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bakshi, S. K. Zaidi, S. Pande, M. Q. Hassan, D. W. Young, M. Montecino, J. B. Lian, A. J. van Wijnen, J. L. Stein, and G. S. Stein
The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes
J. Cell Sci.,
December 1, 2008;
121(23):
3981 - 3990.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Berg, M. Fliegauf, J. Burger, M. S. Staege, S. Liu, N. Martinez, O. Heidenreich, S. Burdach, T. Haferlach, M. H. Werner, et al.
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO
Haematologica,
November 1, 2008;
93(11):
1728 - 1733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Salat, R. Liefke, J. Wiedenmann, T. Borggrefe, and F. Oswald
ETO, but Not Leukemogenic Fusion Protein AML1/ETO, Augments RBP-J{kappa}/SHARP-Mediated Repression of Notch Target Genes
Mol. Cell. Biol.,
May 15, 2008;
28(10):
3502 - 3512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Fazi, G. Zardo, V. Gelmetti, L. Travaglini, A. Ciolfi, L. Di Croce, A. Rosa, I. Bozzoni, F. Grignani, F. Lo-Coco, et al.
Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia
Blood,
May 15, 2007;
109(10):
4432 - 4440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. F. Peterson, M. Yan, and D.-E. Zhang
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO
Blood,
May 15, 2007;
109(10):
4392 - 4398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wichmann, L. Chen, M. Heinrich, D. Baus, E. Pfitzner, M. Zornig, O. G. Ottmann, and M. Grez
Targeting the Oligomerization Domain of ETO Interferes with RUNX1/ETO Oncogenic Activity in t(8;21)-Positive Leukemic Cells
Cancer Res.,
March 1, 2007;
67(5):
2280 - 2289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Claus, M. Fliegauf, M. Stock, J. A. Duque, M. Kolanczyk, and M. Lubbert
Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression
J. Leukoc. Biol.,
December 1, 2006;
80(6):
1462 - 1472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Hamelin, C. Letourneux, P.-H. Romeo, F. Porteu, and M. Gaudry
Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation
Blood,
April 15, 2006;
107(8):
3106 - 3113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thomas, A. Gessner, H.-P. Vornlocher, P. Hadwiger, J. Greil, and O. Heidenreich
Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells
Blood,
November 15, 2005;
106(10):
3559 - 3566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Sledz and B. R. G. Williams
RNA interference in biology and disease
Blood,
August 1, 2005;
106(3):
787 - 794.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|